Great Resources for the Management of Young People on the Autism Spectrum
Below is a list of resources for professionals who work with children and adolescents on the autism spectrum:
1. Afzal N, Murch S, Thirrupathy K, Berger L, Fagbemi A, Heuschkel R. Constipation with acquired megarectum in children with autism.Pediatrics.2003;112 :939– 942
2. Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord.2003;33 :527– 534
3. Aman MG, Novotny S, Samango-Sprouse C, et al. Outcome measures for clinical drug trials in autism. CNS Spectr.2004;9 :36– 47
4. Aman MG. Management of hyperactivity and other acting-out problems in autism spectrum disorder. Semin Pediatr Neurol.2004;11 :225– 228
5. American Academy of Pediatrics, Committee on Children With Disabilities. Auditory integration training and facilitated communication for autism. Pediatrics.1998;102 :431– 433
6. American Academy of Pediatrics, Committee on Children With Disabilities. Counseling families who choose complementary and alternative medicine for their child with chronic illness or disability [published correction appears in Pediatrics. 2001;108:507].Pediatrics.2001;107 :598– 601
7. American Academy of Pediatrics, Medical Home Initiatives for Children With Special Needs Project Advisory Committee. The medical home.Pediatrics.2004;113(5 suppl) :1545– 1547
8. American Academy of Pediatrics. Understanding Autism Spectrum Disorders [pamphlet]. Elk Grove Village, IL: American Academy of Pediatrics; 2005
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Publishing; 2000
10. American Speech-Language-Hearing Association, Ad Hoc Committee on Autism Spectrum Disorders. Principles for speech-language pathologists in diagnosis, assessment, and treatment of autism spectrum disorders across the life span. Available at:www.asha.org/NR/rdonlyres/D0370FEA-98EF-48EE-A9B6-952913FB131B/0/v3TR_autismLSpan.pdf. Accessed February 22,2007
11. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry.2007;61 :551– 553
12. Anderson SR, Avery DL, DiPietro EK, Edwards GL, Christian WP. Intensive home-based intervention with autistic children. Educ Treat Child.1987;10 :352– 366
13. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry.2006;45 :1196– 1205
14. Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry.2003;42:1443– 1450
15. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders: Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2002. MMWR Surveill Summ.2007;56 :12– 28
16. Bågenholm A, Gillberg C. Psychosocial effects on siblings of children with autism and mental retardation: a population-based study. J Ment Defic Res.1991;35 :291– 307
17. Ballaban-Gil K, Tuchman R. Epilepsy and epileptiform EEG: association with autism and language disorders. Ment Retard Dev Disabil Res Rev.2000;6 :300– 308
18. Baranek GT. Efficacy of sensory and motor interventions for children with autism. J Autism Dev Disord.2002;32 :397– 422
19. Birnbrauer JS, Leach DJ. The Murdoch Early Intervention Program after 2 years. Behav Change.1993;10 :63– 74
20. Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ.2002;325 :419– 421
21. Bolman WM, Richmond JA. A double-blind, placebo controlled pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord.1999;29 :191– 194
22. Bondy A, Frost L. The picture exchange communication system. Focus Autistic Behav.1994;9 :1– 19
23. Bondy A, Frost L. The picture exchange communication system. Semin Speech Lang.1998;19 :373– 388
24. Bosch J, Van Dyke C, Smith SM, Poulton S. Role of medical conditions in the exacerbation of self-injurious behavior: an exploratory study. Ment Retard.1997;35 :124– 130
25. Bostic JQ, Rho Y. Target-symptom psychopharmacology: between the forest and the trees. Child Adolesc Psychiatr Clin N Am.2006;15 :289– 302
26. Bouma R, Schweitzer R. The impact of chronic childhood illness on family stress: a comparison between autism and cystic fibrosis. J Clin Psychol.1990;46 :722– 730
27. Bowers L. An audit of referrals of children with autistic spectrum disorder to the dietetic service. J Hum Nutr Diet.2002;15 :141– 144
28. Bregman JD, Zager D, Gerdtz J. Behavioral interventions. In: Volkmar FR, Paul R, Klin A, Cohen D, eds. Handbook of Autism and Pervasive Developmental Disorders. 3rd ed. Vol II. Hoboken NJ: John Wiley & Sons;2005:897– 924
29. Brereton AV, Tonge BJ, Einfeld SL. Psychopathology in children and adolescents with autism compared to young people with intellectual disability. J Autism Dev Disord.2006;36 :863– 870
30. Brown MJ, Willis T, Omalu B, Leiker R. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003–2005.Pediatrics.2006;118(2) . Available at:www.pediatrics.org/cgi/content/full/118/2/e534
31. Bruinsma Y, Koegel RL, Koegel LK. Joint attention and children with autism: a review of the literature. Ment Retard Dev Disabil Res Rev.2004;10 :169– 175
32. Buchsbaum MS, Hollander E, Haznedar MM, et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol.2001;4 :119– 125
33. Buitelaar JK, van der Gaag RJ, van der Hoeven J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry.1998;59 :56– 59
34. Campbell JM. Efficacy of behavioral interventions for reducing problem behavior in persons with autism: a quantitative synthesis of single-subject research. Res Dev Disabil.2003;24 :120– 138
35. Canitano R, Luchetti A, Zappella M. Epilepsy, electroencephalographic abnormalities, and regression in children with autism. J Child Neurol.2005;20 :27– 31
36. Cardinal DN, Hanson D, Wakeham J. Investigation of authorship in facilitated communication. Ment Retard.1996;34 :231– 242
37. Challman TD, Voigt RG, Myers SM. Nonstandard therapies in developmental disabilities. In: Accardo PJ, ed. Capute & Accardo's Neurodevelopmental Disabilities in Infancy and Childhood: Vol I. Neurodevelopmental Diagnosis and Treatment. 3rd ed. Baltimore, MD: Paul H. Brookes; 2008:721– 743
38. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol.2004;14 :372– 394
39. Chez MG, Chang M, Krasne V, Coughlan C, Kominsky M, Schwartz A. Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005.Epilepsy Behav.2006;8 :267– 271
40. Christison GW, Ivany K. Elimination diets in autism spectrum disorders: any wheat amidst the chaff? J Dev Behav Pediatr.2006;27(2 suppl) :S162– S171
41. Christodulu KV, Durand VM. Reducing bedtime disturbance and night waking using positive bedtime routines and sleep restriction. Focus Autism Other Dev Disabl.2004;19 :130– 139
42. Cohen H, Amerine-Dickens M, Smith T. Early intensive behavioral treatment: replication of the UCLA model in a community setting. J Dev Behav Pediatr.2006;27(2 suppl) :S145– S155
43. Connor DF, Ozbayrak KR, Benjamin S, Ma Y, Fletcher KE. A pilot study of nadolol for overt aggression in developmentally delayed individuals. J Am Acad Child Adolesc Psychiatry.1997;36 :826– 834
44. Cooley WC. Redefining primary pediatric care for children with special health care needs: the primary care medical home. Curr Opin Pediatr.2004;16 :689– 692
45. Croen LA, Najjar DV, Ray GT, Lotspeich L, Bernal P. A comparison of health care utilization and costs of children with and without autism spectrum disorders in a large group-model health plan.Pediatrics.2006;118(4) . Available at:www.pediatrics.org/cgi/content/full/118/4/e1203
46. Dawson G, Osterling J. Early intervention in autism. In: Guralnick MJ, ed. The Effectiveness of Early Intervention: Second Generation Research. Baltimore, MD: Brookes; 1997:307– 326
47. Dawson G, Watling R. Interventions to facilitate auditory, visual, and motor integration in autism: a review of the evidence. J Autism Dev Disord.2000;30 :415– 421
48. DelGiudice-Asch G, Simon L, Schmeidler J, Cunningham-Rundles C, Hollander E. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord.1999;29 :157– 160
49. DeLong R. Children with autistic spectrum disorder and a family history of affective disorder. Dev Med Child Neurol.1994;36 :674– 687
50. DeMyer MK, Hingtgen JN, Jackson RK. Infantile autism reviewed: a decade of research. Schizophr Bull.1981;7 :388– 451
51. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry.1993;17 :765– 774
52. Dosreis S, Weiner CL, Johnson L, Newschaffer CJ. Autism spectrum disorder screening and management practices among general pediatric providers. J Dev Behav Pediatr.2006;27(2 suppl) :S88– S94
53. Dumas JE, Wolf LC, Fisman SN, et al. Parenting stress, child behavior problems, and dysphoria in parents of children with autism, Down syndrome, behavior disorders, and normal development.Exceptionality.1991;2 :97– 110
54. Eikeseth S, Smith T, Jahr E, Eldevik S. Intensive behavioral treatment at school for 4- to 7-year-old children with autism: a 1-year comparison controlled study. Behav Modif.2002;26 :49– 68
55. Elder JH, Shankar M, Shuster J, Theriaque D, Burns S, Sherill L. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord.2006;36 :413– 420
56. Eldevik S, Eikeseth S, Jahr E, Smith T. Effects of low-intensity behavioral treatment for children with autism and mental retardation. J Autism Dev Disord.2006;36 :211– 224
57. Erickson CA, Stigler KA, Corkins MR, Posey DJ, Fitzgerald JF, McDougle CJ. Gastrointestinal factors in autistic disorder: a critical review. J Autism Dev Disord.2005;35 :713– 727
58. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry.1992;53 :77– 82
59. Findling RL, Maxwell K, Scotese-Wojtila L, Huang J, Yamashita T, Wiznitzer M. High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord.1997;27:467– 478
60. Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics.2001;108(4) . Available at:www.pediatrics.org/cgi/content/full/108/4/e58
61. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics.2006;118(1) . Available at: www.pediatrics.org/cgi/content/full/118/1/e139
62. FREE Full Text
63. Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord.2006;36 :741– 752
64. Gold C, Wigram T, Elefant C. Music therapy in autistic spectrum disorder. Cochrane Database Syst Rev.2006;(2) :CD004381
65. Gold N. Depression and social adjustment in siblings of boys with autism. J Autism Dev Disord.1993;23 :147– 163
66. Goldstein H. Communication intervention for children with autism: a review of treatment efficacy. J Autism Dev Disord.2002;32 :373– 396
67. Gray C, McAndrew S. My Social Stories Book. London, England: Jessica Kingsley; 2002
68. Gray DE. Ten years on: a longitudinal study of families of children with autism. J Intellect Dev Disabil.2002;27 :215– 222
69. Greenspan SI, Wieder S. Developmental patterns and outcomes in infants and children with disorders in relating and communicating: a chart review of 200 cases of children with autistic spectrum diagnoses. J Dev Learn Disord.1997;1 :87– 141
70. Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord.1996;26 :439– 452
71. Gupta VB. Complementary and alternative treatments for autism. In: Gupta VB, ed. Autistic Spectrum Disorders in Children (Pediatric Habilitation Series Volume 12). New York, NY: Marcel Dekker; 2004:239– 254
72. Gutstein SE, Sheely RK. Relationship Development Intervention With Children, Adolescents, and Adults. New York, NY: Jessica Kingsley; 2002
73. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord.2000;30 :245– 255
74. Handleman JS, Harris SL. Preschool Education Programs for Children With Autism. 2nd ed. Austin, TX: Pro-Ed; 2000
75. Hardan AY, Jou RJ, Handen BL. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol.2004;14 :426– 432
76. Harrington JW, Rosen L, Garnecho A, Patrick PA. Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice. J Dev Behav Pediatr.2006;27 :S156– S161
77. Harris SL, Handleman JS, Jennett HK. Models of educational intervention for students with autism: home, center, and school-based programming. In: Volkmar FR, Paul R, Klin A, Cohen D, eds. Handbook of Autism and Pervasive Developmental Disorders. 3rd ed. Vol II. Hoboken, NJ: John Wiley & Sons; 2005:1043– 1054
78. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry.2001;62 :530– 534
79. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology.2005;30 :582– 589
80. Hollander E, Phillips AT, Yeh CC. Targeted treatments for symptom domains in child and adolescent autism. Lancet.2003;362 :732– 734
81. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol.2006;9 :209– 213
82. Horner RH, Carr EG, Strain PS, Todd AW, Reed HK. Problem behavior interventions for young children with autism: a research synthesis. J Autism Dev Disord.2002;32 :423– 446
83. Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr.1999;135 :559– 563
84. Horvath K, Perman JA. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep.2002;4 :251– 258
85. Howard JS, Sparkman CR, Cohen HG, Green G, Stanislaw H. A comparison of intensive behavior analytic and eclectic treatments for young children with autism. Res Dev Disabil.2005;26 :359– 383
86. Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for children with autism. J Child Psychol Psychiatry.2004;45 :212– 229
87. Howlin P. Outcomes in autism spectrum disorders. In: Volkmar FR, Paul R, Klin A, Cohen D, eds. Handbook of Autism and Pervasive Developmental Disorders. 3rd ed. Vol II. Hoboken, NJ: John Wiley & Sons;2005:201– 220
88. Hrdlicka M, Komarek V, Propper L, et al. Not EEG abnormalities but epilepsy is associated with autistic regression and mental functioning in childhood autism. Eur Child Adolesc Psychiatry.2004;13 :209– 213
89. Hyman SL, Levy SE. Introduction: novel therapies in developmental disabilities—hope, reason, and evidence. Ment Retard Dev Disabil Res Rev.2005;11 :107– 109
90. Ingrassia A, Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders: a case series. Eur Child Adolesc Psychiatry.2005;14 :34– 40
91. Jacobson JW, Mulick JA, Schwartz AA. A history of facilitated communication: science, pseudoscience, and antiscience. Science Working Group on Facilitated Communication. Am Psychol.1995;50 :750– 765
92. James SJ, Cutler P, Melnyks S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr.2004;80 :1611– 1617
93. Jan JE, Freeman RD. Melatonin therapy for circadian rhythm sleep disorders in children with multiple disabilities: what have we learned in the last decade? Dev Med Child Neurol.2004;46 :776– 782
94. Jaselskis CA, Cook EH, Fletcher E, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol.1992;12 :322– 327
95. Johnson CP, Myers SM; American Academy of Pediatrics, Council on Children With Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics.2007;120 :1183– 1215
96. Jou RJ, Handen BL, Hardan AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol.2005;15 :325– 330
97. Kagan-Kushnir T, Roberts SW, Snead OC III. Screening electroencephalograms in autism spectrum disorders: evidence-based guideline. J Child Neurol.2005;20 :197– 206
98. Kasari C, Freeman S, Paparella T. Joint attention and symbolic play in young children with autism: a randomized controlled intervention study. J Child Psychol Psychiatry.2006;47 :611– 620
99. Kerbeshian J, Burd L, Fisher W. Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. J Clin Psychopharmacol.1987;7 :401– 405
100. Kern JK, Miller VS, Cauller PL, Kendall PR, Mehta PJ, Dodd M. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol.2001;16 :169– 173
101. Klin A, Volkmar FR. Treatment and intervention guidelines for individuals with Asperger syndrome. In: Klin A, Volkmar FR, Sparrow SS, eds. Asperger Syndrome. New York, NY: Guilford Press; 2000:340– 366
102. Koegel LK. Interventions to facilitate communication in autism. J Autism Dev Disord.2000;30 :383– 391
103. Konstantareas MM, Lunsky YJ. Sociosexual knowledge, experience, attitudes, and interests of individuals with autistic disorder and developmental delay. J Autism Dev Disord.1997;27 :397– 413
104. Kowatch RA, DelBello MD. Pediatric bipolar disorder: emerging diagnostic and treatment approaches. Child Adolesc Psychiatr Clin N Am.2006;15 :73– 108
105. Krasny L, Williams BJ, Provencal S, Ozonoff S. Social skills interventions for the autism spectrum: essential ingredients and a model curriculum.Child Adolesc Psychiatr Clin N Am.2003;12 :107– 122
106. Kuddo T, Nelson KB. How common are gastrointestinal disorders in children with autism? Curr Opin Pediatr.2003;15 :339– 343
107. Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuro Endocrinol Lett.2000;21 :31– 34
108. La Camera RG, La Camera AC. Routine health care. In: Cohen DJ, Volkmar FR, eds. Handbook of Autism and Pervasive Developmental Disorders. 2nd ed. New York, NY: John Wiley & Sons; 1997:730– 740
109. Langworthy-Lam KS, Aman MG, Van Bourgondien ME. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the autism society of North Carolina. J Child Adolesc Psychopharmacol.2002;12 :311– 321
110. Layton TL. Language training with autistic children using four different modes of presentation. J Commun Disord.1988;21 :333– 350
111. Lee DO. Menstrually related self-injurious behavior in adolescents with autism. J Am Acad Child Adolesc Psychiatry.2004;43 :1193
112. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders.Ment Retard Dev Disabil Res Rev.2005;11 :131– 142
113. Levy SE, Mandell DS, Merhar S, Ittenbach RF, Pinto-Martin JA. Use of complementary and alternative medicine among children recently diagnosed with autistic spectrum disorder. J Dev Behav Pediatr.2003;24:418– 423
114. Leyfer OT, Folstein SE, Bacalman S, et al. Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord.2006;36 :849– 861
115. Lightdale JR, Siegel B, Heyman MB. Gastrointestinal symptoms in autistic children. Clin Perspect Gastroenterol.2001;1 :56– 58
116. Liptak GS, Orlando M, Yingling JT, et al. Satisfaction with primary health care received by families of children with developmental disabilities. J Pediatr Health Care.2006;20 :245– 252
117. Liptak GS, Stuart T, Auinger P. Health care utilization and expenditures for children with autism: data from U.S. national samples. J Autism Dev Disord.2006;36 :871– 879
118. Lord C, Schopler E. The role of age at assessment, developmental level, and test in the stability of intelligence scores in young autistic children. J Autism Dev Disord.1989;19 :483– 499
119. Lorimer PA, Simpson RL, Myles BS, et al. The use of social stories as a preventative behavioral intervention in a home setting with a child with autism. J Posit Behav Interv.2002;4 :53– 60
120. Lovaas OI, ed. Teaching Individuals With Developmental Delays: Basic Intervention Techniques. Austin, TX: Pro-Ed; 2003
121. Lovaas OI. Behavioral treatment and normal educational and intellectual functioning in young autistic children. J Consult Clin Psychol.1987;55 :3– 9
122. Mahoney G, McDonald J. Responsive Teaching: Parent-Mediated Developmental Intervention. Baltimore, MD: Paul H. Brookes; 2003
123. Mahoney G, Perales F. Relationship-focused early intervention with children with pervasive developmental disorders and other disabilities: a comparative study. J Dev Behav Pediatr.2005;26 :77– 85
124. Malow BA, McGrew SG, Harvey M, et al. Impact of treating sleep apnea in a child with autism spectrum disorder. Pediatr Neurol.2006;34 :325– 328
125. Malow BA. Sleep disorders, epilepsy, and autism. Ment Retard Dev Disabil Res Rev.2004;10 :122– 125
126. Mandell DS, Cao J, Ittenbach R, Pinto-Martin J. Medicaid expenditures for children with autistic spectrum disorders: 1994 to 1999. J Autism Dev Disord.2006;36 :475– 485
127. Marans WD, Rubin E, Laurent A. Addressing social communication skills in individuals with high-functioning autism and Asperger syndrome: critical priorities in educational programming. In: Volkmar FR, Paul R, Klin A, Cohen D, eds. Handbook of Autism and Pervasive Developmental Disorders. 3rd ed. Vol II. Hoboken, NJ: John Wiley & Sons; 2005:977– 1002
128. Marcus LM, Kunce LJ, Schopler E. Working with families. In: Volkmar FR, Paul R, Klin A, Cohen D, eds. Handbook of Autism and Pervasive Developmental Disorders. 3rd ed. Vol II. Hoboken, NJ: John Wiley & Sons;2005:1055– 1086
129. Marcus LM, Lansing M, Andrews CE, Schopler E. Improvement of teaching effectiveness in parents of autistic children. J Am Acad Child Psychiatry.1978;17 :625– 639
130. Mastergeorge AM, Rogers SJ, Corbett BA, et al. Nonmedical interventions for autism spectrum disorders. In: Ozonoff S, Rogers SJ, Hendren RL, eds. Autism Spectrum Disorders: A Research Review for Practitioners. Washington, DC: American Psychiatric Publishing;2003:133– 160
131. Matson JL, Benavidez DA, Compton LS, Paclawskyj T, Baglio C. Behavioral treatment of autistic persons: a review of research from 1980 to the present. Res Dev Disabil.1996;17 :433– 465
132. McConnell S. Interventions to facilitate social interaction for young children with autism: review of available research and recommendations for educational intervention and future research. J Autism Dev Disord.2002;32 :351– 372
133. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med.2002;347 :314– 321
134. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry.1996;53 :1001– 1008
135. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry.2005;162 :1142– 1148
136. McEachin JJ, Smith T, Lovaas OI. Long-term outcome for children with autism who received early intensive behavioral treatment. Am J Ment Retard.1993;97 :359– 372
137. Mehta UC, Patel I, Castello FV. EEG sedation for children with autism. J Dev Behav Pediatr.2004;25 :102– 104
138. Melmed RD, Schneider CK, Fabes RA, Philips J, Reichelt K. Metabolic markers and gastrointestinal symptoms in children with autism and related disorders [abstract]. J Pediatr Gastroenterol Nutr.2000;31(suppl 2):S31
139. Meltzer LJ, Mindell JA. Nonpharmacologic treatments for pediatric sleeplessness. Pediatr Clin North Am.2004;51 :135– 151
140. Mesibov GB, Shea V, Schopler E. The TEACCH Approach to Autism Spectrum Disorders. New York, NY: Kluwer Academic/Plenum; 2005
141. Mesibov GB. Formal and informal measures on the effectiveness or the TEACCH programme. Autism.1997;1 :25– 35
142. Millar DC, Light JC, Schlosser RW. The impact of augmentative and alternative communication intervention on the speech production of individuals with developmental disabilities: a research review. J Speech Lang Hear Res.2006;49 :248– 264
143. Milward C, Ferriter M, Calver S, et al. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev.2004;(2):CD003498
144. Molloy CA, Manning-Courtney P. Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders.Autism.2003;7 :165– 171
145. Moore ML, Eichner SF, Jones JR. Treating functional impairment of autism with selective serotonin-reuptake inhibitors. Ann Pharmacother.2004;38 :1515– 1519
146. Mostert MP. Facilitated communication since 1995: a review of published studies. J Autism Dev Disord.2001;31 :287– 313
147. Mudford OC, Cross BA, Breen S, et al. Auditory integration training for children with autism: no behavioral benefits detected. Am J Ment Retard.2000;105 :118– 129
148. Murphy N. Sexuality in children and adolescents with disabilities. Dev Med Child Neurol.2005;47 :640– 644
149. Murphy NA, Elias ER; American Academy of Pediatrics, Council on Children With Disabilities. Sexuality of children and adolescents with developmental disabilities. Pediatrics.2006;118 :398– 403
150. Myers SM, Challman TD. Psychopharmacology: an approach to management in autism and intellectual disabilities. In: Accardo PJ, ed.Capute & Accardo's Neurodevelopmental Disabilities in Infancy and Childhood: Vol I. Neurodevelopmental Diagnosis and Treatment. 3rd ed. Baltimore, MD: Paul H. Brookes; 2008:577– 614
151. Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother.2007;8 :1579– 1603
152. Namerow LB, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr.2003;24 :104– 108
153. National Center for Complementary and Alternative Medicine. Expanding horizons of healthcare: five year strategic plan 2001–2005. Washington, DC: US Department of Health and Human Services; 2000
154. National Research Council, Committee on Educational Interventions for Children with Autism. Educating Children With Autism. Lord C, McGee JP, eds. Washington, DC: National Academies Press; 2001
155. Nickel R. Controversial therapies for young children with developmental disabilities. Infants Young Child.1996;8 :29– 40
156. Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev.2005;(4) :CD003497
157. Olley JG. Curriculum and classroom structure. In: Volkmar FR, Paul R, Klin A, Cohen D, eds. Handbook of Autism and Pervasive Developmental Disorders. 3rd ed. Vol II. Hoboken, NJ: John Wiley & Sons; 2005:863– 881
158. O'Neill R, Horner R, Albin R, et al. Functional Assessment and Program Development for Problem Behavior: A Practical Handbook. Pacific Grove, CA: Brookes/Cole Publishing; 1996
159. Owens JA, Babcock D, Blumer J, et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches—a consensus meeting summary. J Clin Sleep Med.2005;1 :49– 59
160. Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry.2005;44 :343– 348
161. Oyane NM, Bjorvatn B. Sleep disturbances in adolescents and young adults with autism and Asperger syndrome. Autism.2005;9 :83– 94
162. Ozonoff S, Cathcart K. Effectiveness of a home program intervention for young children with autism. J Autism Dev Disord.1998;28 :25– 32
163. Paavonen EJ, Nieminen-von Wendt T, Vanhala R, Aronen ET, von Wendt L. Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. J Child Adolesc Psychopharmacol.2003;13 :83– 95
164. Patzold LM, Richdale AL, Tonge BJ. An investigation into sleep characteristics of children with autism and Asperger's disorder. J Paediatr Child Health.1998;34 :528– 533
165. Paul R, Sutherland D. Enhancing early language in children with autism spectrum disorders. In: Volkmar FR, Paul R, Klin A, Cohen D, eds.Handbook of Autism and Pervasive Developmental Disorders. 3rd ed. Vol II. Hoboken, NJ: John Wiley & Sons; 2005:946– 976
166. Pavone P, Incorpora G, Fiumara A, Parano E, Trifiletti RR, Ruggieri M. Epilepsy is not a prominent feature of primary autism.Neuropediatrics.2004;35 :207– 210
167. Perry, DW, Marston GM, Hinder SA. The phenomenology of depressive illness in people with a learning disability and autism. Autism.2001;5:265– 275
168. Phillips L, Appleton RE. Systematic review of melatonin treatment in children with neurodevelopmental disabilities and sleep impairment. Dev Med Child Neurol.2004;46 :771– 775
169. Pickett JA, Paculdo DR, Shavelle RM, Strauss DJ. 1998–2002 update on “Causes of Death in Autism. ” J Autism Dev Disord.2006;36 :287– 288
170. Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol.1998;13 :79– 82
171. Polimeni MA, Richdale AL, Francis AJ. A survey of sleep problems in autism, Asperger's disorder and typically developing children. J Intellect Disabil Res.2005;49 :260– 268
172. Posey DJ, Erickson CA, Stigler KA, McDougle CJ. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol.2006;16 :181– 186
173. Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol.2001;11:267– 277
174. Posey DJ, McDougle CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry.2000;8 :45– 63
175. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol.2004;14 :233– 241
176. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol.2006;16 :599– 610
177. Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord.1995;25:283– 294
178. Ratey JJ, Mikkelsen E, Sorgi P, et al. Autism: the treatment of aggressive behaviors. J Clin Psychopharmacol.1987;7 :35– 41
179. Reed MD, Findling RL. Overview of current management of sleep disturbances in children: I—pharmacotherapy. Curr Ther Res.2002;63(suppl B) :B18– B37
180. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry.2005;62:1266– 1274
181. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry.2005;162 :1361– 1369
182. Reynhout G, Carter M. Social stories for children with disabilities. J Autism Dev Disord.2006;36 :445– 469
183. Rogers SJ, DiLalla DL. A comparative study of the effects of a developmentally based instructional model on young children with autism and young children with other disorders of behavior and development. Top Early Child Spec Educ.1991;11 :29– 47
184. Rogers SJ, Herbison JM, Lewis HC, et al. An approach for enhancing the symbolic, communicative, and interpersonal functioning of young children with autism or severe emotional handicaps. J Div Early Child.1986;10 :135– 148
185. Rogers SJ, Lewis H. An effective day treatment model for young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry.1989;28 :207– 214
186. Rogers SJ, Lewis HC, Reis K. An effective procedure for training early special education teams to implement a model program. J Div Early Child.1987;11 :180– 188
187. Rogers SJ, Ozonoff S. Annotation: what do we know about sensory dysfunction in autism? A critical review of the empirical evidence. J Child Psychol Psychiatry.2005;46 :1255– 1268
188. Rogers SJ. Empirically supported comprehensive treatments for young children with autism. J Clin Child Psychol.1998;27 :168– 179
189. Rogers SJ. Interventions that facilitate socialization in children with autism. J Autism Dev Disord.2000;30 :399– 409
190. Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr.2002;23 :225– 230
191. Sallows GO, Graupner TD. Intensive behavioral treatment for children with autism: four-year outcome and predictors. Am J Ment Retard.2005;110:417– 438
192. Sandler A. Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev.2005;11 :164– 170
193. Sankar E. Initial treatment of epilepsy with antiepileptic drugs: pediatric issues. Neurology.2004;63(10 suppl 4) :S30– S39
194. Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. J Child Adolesc Psychopharmacol.2006;16 :589– 598
195. Schaaf RC, Miller LJ. Occupational therapy using a sensory integrative approach for children with developmental disabilities. Ment Retard Dev Disabil Res Rev.2005;11 :143– 148
196. Schepis MM, Reid DH, Behrmann MM, Sutton KA. Increasing communicative interactions of young children with autism using a voice output communication aid and naturalistic teaching. J Appl Behav Anal.1998;31 :561– 578
197. Schopler E, Mesibov GB, Baker A. Evaluation of treatment for autistic children and their parents. J Am Acad Child Psychiatry.1982;21 :262– 267
198. Schreck KA, Mulick JA, Smith AF. Sleep problems as possible predictors of intensified symptoms of autism. Res Dev Disabil.2004;25 :57– 66
199. Schreibman L, Ingersoll B. Behavioral interventions to promote learning in individuals with autism. In: Volkmar FR, Paul R, Klin A, Cohen D, eds.Handbook of Autism and Pervasive Developmental Disorders. 3rd ed. Vol II. Hoboken, NJ: John Wiley & Sons; 2005:882– 896
200. Seltzer MM, Shattuck P, Abbeduto L, Greenberg JS. Trajectory of development in adolescents and adults with autism. Ment Retard Dev Disabil Res Rev.2004;10 :234– 247
201. Shannon M, Graef JW. Lead intoxication in children with pervasive developmental disorders. J Toxicol Clin Toxicol.1996;34 :177– 181
202. Shavelle RM, Strauss DJ, Pickett J. Causes of death in autism. J Autism Dev Disord.2001;31 :569– 576
203. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics.2004;114(5) . Available at:www.pediatrics.org/cgi/content/full/114/5/e634
204. Short AB. Short-term treatment outcome using parents as co-therapists for their own autistic children. J Child Psychol Psychiatry.1984;25 :443– 458
205. Sibinga EM, Ottolini MC, Duggan AK, Wilson MH. Parent-pediatrician communication about complementary and alternative medicine use for children. Clin Pediatr (Phila).2004;43 :367– 373
206. Sinha Y, Silove N, Wheeler D, Williams K. Auditory integration training and other sound therapies for autism spectrum disorders. Cochrane Database Syst Rev.2004;(1) :CD003681
207. Sinha Y, Silove N, Wheeler D, Williams K. Auditory integration training and other sound therapies for autism spectrum disorders: a systematic review. Arch Dis Child.2006;91 :1018– 1022
208. Smith MD, Haas PJ, Belcher RG. Facilitated communication: the effects of facilitator knowledge and level of assistance on output. J Autism Dev Disord.1994;24 :357– 367
209. Smith T, Groen AD, Wynne JW. Randomized trial of intensive early intervention for children with pervasive developmental disorder. Am J Ment Retard.2000;105 :269– 285
210. Smith T, Perry A. A sibling support group for brothers and sisters of children with autism. J Dev Disabil.2005;11 :77– 88
211. Smith T. Outcome of early intervention for children with autism. Clin Psychol Sci Pract.1999;6 :33– 49
212. Smits MG, van Stel HF, van der Heijden K, Meijer AM, Coenan AM, Kerkhof GA. Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial. J Am Acad Child Adolesc Psychiatry.2003;42 :1286– 1293
213. Steingard R, Biederman J. Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. J Am Acad Child Adolesc Psychiatry.1987;26 :932– 935
214. Steingard RJ, Connor DF, Au T. Approaches to psychopharmacology. In: Bauman ML, Kemper TL, eds. The Neurobiology of Autism. 2nd ed. Baltimore, MD: Johns Hopkins University Press; 2005:79– 102
215. Stigler KA, Posey DJ, McDougle CJ. Ramelteon for insomnia in two youths with autistic disorder. J Child Adolesc Psychopharmacol.2006;16:631– 636
216. Sturmey P. Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials. Res Dev Disabil.2005;26 :87– 97
217. Sugie Y, Sugie H, Fukuda T, et al. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. J Autism Dev Disord.2005;35 :377– 385
218. Syzmanski LS, King B, Goldberg B, et al. Diagnosis of mental disorders in people with mental retardation. In: Reiss S, Aman MG, eds.Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, OH: Ohio State University Nisonger Center; 1998:3– 17
219. Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population-based study.BMJ.2002;324 :393– 396
220. Taylor BA, Jasper S. Teaching programs to increase peer interaction. In: Maurice C, Green G, Foxx RM, eds. Making a Difference: Behavioral Intervention for Autism. Austin, TX: Pro-Ed; 2001:97– 162
221. Taylor BA. Teaching peer social skills to children with autism. In: Maurice C, Green G, Foxx RM, eds. Making a Difference: Behavioral Intervention for Autism. Austin, TX: Pro-Ed; 2001:83– 96
222. Tordjman S, Anderson GM, Pichard N, Charbuy H, Touitou Y. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biol Psychiatry.2005;57 :134– 138
223. Torrente F, Anthony A, Heuschkel RB, Thomson MA, Ashwood P, Murch SH. Focal-enhanced gastritis in regressive autism with features distinct from Crohn's and Helicobacter pylori gastritis. Am J Gastroenterol.2004;99 :598– 605
224. Towbin KE. Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome. Child Adolesc Psychiatr Clin N Am.2003;12 :23– 45
225. Troost PW, Lahuis BE, Steenuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry.2005;44:1137– 1144
226. Tsakanikos E, Costello H, Holt G, et al. Psychopathology in adults with autism and intellectual disability. J Autism Dev Disord.2006;36 :1123– 1129
227. Tuchman R, Rapin I, Shinnar S. Autistic and dysphasic children II: epilepsy [published correction appears in Pediatrics. 1992;90:264].Pediatrics.1991;88 :1219– 1225
228. Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol.2002;1 :352– 358
229. Tuchman RF, Rapin I. Regression in pervasive developmental disorders: seizures and epileptiform electroencephalogram correlates.Pediatrics.1997;99 :560– 566
230. Turk J. Melatonin supplementation for severe and intractable sleep disturbance in young people with genetically determined developmental disabilities: short review and commentary. J Med Genet.2003;40 :793– 796
231. Valicenti-McDermott M, McVicar K, Rapin I, Wershil BK, Cohen H, Shinnar S. Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr.2006;27(2 suppl) :S128– S136
232. Venter AC, Lord C, Schopler E. A follow-up study of high-functioning autistic children. J Child Psychol Psychiatry.1992;33 :489– 507
233. Vitiello B. An update on publicly funded multisite trials in pediatric psychopharmacology. Child Adolesc Psychiatr Clin N Am.2006;15 :1– 12
234. Volkmar FR, Nelson DS. Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry.1990;29 :127– 129
235. Volkmar FR, Wiesner LA, Westphal A. Healthcare issues for children on the autism spectrum. Curr Opin Psychiatry.2006;19 :361– 366
236. Weiskop S, Richdale A, Matthews J. Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome. Dev Med Child Neurol.2005;47 :94– 104
237. Weiss M. Differential rates of skill acquisition and outcomes of early intensive behavioral intervention for autism. Behav Interv.1999;14 :3– 22
238. Weiss MJ, Harris SL. Teaching social skills to people with autism. Behav Modif.2001;25 :785– 802
239. Whalen C, Schreibman L. Joint attention training for children with autism using behavior modification procedures. J Child Psychol Psychiatry.2003;44 :456– 468
240. Wieder S, Greenspan SI. Can children with autism master the core deficits and become empathetic, creative, and reflective? A ten to fifteen year follow-up of a subgroup of children with autism spectrum disorders (ASD) who received a comprehensive developmental, individual-difference, relationship-based (DIR) approach. J Dev Learn Disord.2005;9:39– 61
241. Wiggs L, Stores G. Sleep patterns and sleep disorders in children with autistic spectrum disorders: insights using parent report and actigraphy.Dev Med Child Neurol.2004;46 :372– 380
242. Williams G, Sears LL, Allaed A. Sleep problems in children with autism.J Sleep Res.2004;13 :265– 268
243. Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev.2005;(3) :CD003495
244. Witwer A, Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J Child Adolesc Psychopharmacol.2005;15 :671– 681
245. Wong HHL, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord.2006;36 :901– 909
246. Zollman C, Vickers A. What is complementary medicine? BMJ.1999;319:693– 696
Mark Hutten, M.A.